Autophagy-Proteostasis Dual Activation

Migration, Crosslink

📖

Autophagy-Proteostasis Dual Activation

active

wiki page Created: 2026-04-02T07:19:34 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-ideas-autophagy-proteostasis-dual-a

📖 Wiki Page

idea1064 wordssynced 2026-04-02

Overview

The autophagy-proteasome system represents the primary cellular machinery for clearing misfolded proteins and damaged organelles. In neurodegenerative diseases, both autophagy and proteasome function decline, leading to accumulation of toxic protein aggregates including [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), alpha-synuclein, and [TDP-43](/mechanisms/tdp-43-proteinopathy)[@tfeb2020][@autophagyproteasome2019]. This therapy proposes simultaneous activation of both pathways to achieve synergistic clearance of pathological protein species that neither pathway can handle alone[@alphasynuclein2018].

Pathway / Mechanism Diagram

graph TD A["Nutrient Deprivation / Stress"] --> B["AMPK Activation"] B --> C["ULK1 Complex Activation"] A --> D["mTORC1 Inhibition"] D --> C C --> E["Phagophore Nucleation (VPS34/Beclin-1)"] E --> F["LC3 Lipidation (LC3-II)"] F --> G["Autophagosome Formation"] G --> H["Cargo Recognition (p62/SQSTM1)"] H --> I["Autophagosome-Lysosome Fusion"] I --> J["Cargo Degradation"] J --> K["Amino Acid Recycling"] K --> L["Cell Survival"] M["Autophagy Impairment in Aging"] --> N["Aggregate Accumulation"] N --> O["Tau, Abeta, alpha-Synuclein Buildup"] O --> P["Neurodegeneration"] style L fill:#1b5e20,color:#e0e0e0 style P fill:#ef5350,color:#e0e0e0 style G fill:#006494,color:#e0e0e0

Rubric Scores

...

Overview

The autophagy-proteasome system represents the primary cellular machinery for clearing misfolded proteins and damaged organelles. In neurodegenerative diseases, both autophagy and proteasome function decline, leading to accumulation of toxic protein aggregates including [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), alpha-synuclein, and [TDP-43](/mechanisms/tdp-43-proteinopathy)[@tfeb2020][@autophagyproteasome2019]. This therapy proposes simultaneous activation of both pathways to achieve synergistic clearance of pathological protein species that neither pathway can handle alone[@alphasynuclein2018].

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Rubric Scores

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7 | Dual activation concept is newer; components individually in trials |
| Mechanistic Rationale | 9 | Strong scientific basis for combining autophagy + proteasome |
| Addresses Root Cause | 9 | Targets protein aggregate clearance, fundamental problem |
| Delivery Feasibility | 6 | Large molecules may have BBB issues; small molecule approaches exist |
| Safety Plausibility | 7 | Autophagy modulation generally safe; proteasome excess needs monitoring |
| Combinability | 9 | Can combine with many other mechanisms |
| Biomarker Availability | 8 | LC3, p62, 20S proteasome activity measurable |
| De-risking Path | 7 | Components in development; combination needs validation |
| Multi-disease Potential | 9 | AD, PD, ALS, Huntington's - all protein aggregation diseases |
| Patient Impact | 8 | High potential for disease modification |

Total: 73/100

Action Plan

Next Experiment: Test dual activation in iPSC [neurons](/entities/neurons) from AD/PD patients

Grant Target: NIH R01 (NIA) — "Dual proteostasis activation for neurodegeneration"

Industry Outreach: Contact companies developing TFEB activators and proteasome modulators

Clinical Protocol: Design biomarker-driven study in early disease patients

Actionable Next Steps

Lab Experiments

Dual activation validation: Test TFEB activator (rapamycin, trehalose)[@tfeb2020] + proteasome enhancer (NEDD8 pathway activator) combination in iPSC-derived neurons from AD and PD patients

Biomarker assay development: Validate LC3, p62, and 20S proteasome activity as pharmacodynamic markers in patient-derived neurons

Efficacy testing: Measure clearance of alpha-synuclein, tau, and TDP-43 aggregates in dual-treated neurons

Dose-optimization study: Determine synergistic dosing for TFEB activation and proteasome enhancement

Animal model testing: Evaluate dual activation in PS19 tauopathy mice and alpha-synuclein preformed fibril mice

Clinical Protocol Design

Patient selection: Enroll early-stage AD (Braak I-II) and PD (Hoehn & Yahr 1-2) patients with biomarker evidence of protein aggregation

Trial design: Randomized, placebo-controlled trial with biomarker primary endpoint (LC3, p62 in CSF)

Dose-finding: Establish maximum tolerated dose for combined TFEB activator + proteasome enhancer

Combination protocol: Plan add-on study with standard-of-care ([cholinesterase inhibitors](/entities/cholinesterase-inhibitors) for AD, dopamine agonists for PD)

Endpoint selection: Primary - change in CSF proteostasis biomarkers; Secondary - clinical scales (ADAS-Cog, MDS-UPDRS)

Company Partnership Opportunities

Denali Therapeutics: Leading TFEB activator developer with BBB platform; natural partnership for dual therapy

Procter & Gamble: Has EGCG and trehalose formulations; could co-develop nutritional formulation

Calico/AbbVie: Longevity-focused R&D with autophagy modulation programs

Alector: Autophagy-focused neurodegeneration company with complementary programs

Cyteir Therapeutics: NEDD8 pathway expertise for proteasome enhancement component

Cross-links

[TFEB](/entities/tfeb)
[Autophagy](/entities/autophagy)
[Proteasome](/mechanisms/ubiquitin-proteasome-system)
[Lysosomal Function](/mechanisms/autophagy-lysosomal-ad)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Tau Protein](/proteins/tau)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Implementation Roadmap

Estimated Timeline (4-5 years to IND)

| Phase | Duration | Key Milestones |
|-------|----------|----------------|
| Discovery & Lead Optimization | 12-15 months | TFEB activator + proteasome enhancer combination screening, in vitro validation |
| IND-enabling studies | 12-15 months | GLP toxicology, CMC development, regulatory pre-IND meetings |
| Phase I | 12 months | Safety, dose-ranging in early AD/PD patients |
| Phase II | 15-18 months | Efficacy signal with LC3, p62, 20S proteasome biomarkers |

Estimated Cost

Discovery & lead optimization: -10M
IND-enabling studies: -12M
Phase I-II trials: 0-35M
Total to Phase II: 4-57M

Academic Centers (Key Opinion Leaders)

University of Michigan — Dr. Ming O. Li (pioneered TFEB autophagy research)

University of Texas Southwestern — Dr. Connie S. Ce (proteostasis, autophagy crosstalk)

Harvard Medical School — Dr. Steven M. Reppert (lysosomal biogenesis)

UCLA — Dr. Gal Bitan (protein aggregation, proteostasis)

Mount Sinai — Dr. Sam Gandy (AD therapeutics, proteostasis)

Potential Industry Partners

Denali Therapeutics — TFEB activator programs, [blood-brain barrier](/entities/blood-brain-barrier) platform

Procter & Gamble — EGCG/trehalose formulations

Calico — Longevity research, autophagy modulation

Alector — Autophagy and neurodegeneration programs

Cyteir Therapeutics — NEDD8 pathway, proteasome modulation

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| TFEB activator CNS penetration | Medium | High | Use blood-brain barrier-penetrant compounds, intranasal delivery |
| Combination toxicity | Medium | Medium | Staged toxicity testing, lowest effective doses |
| Biomarker assay validation | Medium | Low | CLIA-certified assay development in parallel |
| Competition with monotherapies | Low | Medium | Emphasize dual mechanism advantage over single-pathway approaches |
| Patient heterogeneity | Medium | Medium | Patient stratification by proteostasis biomarker profiles |

Regulatory Strategy

Fast Track: Possible for rare subtypes (e.g., PSP, CBD)
Biomarker-driven trials: Use LC3/p62 as surrogate endpoints for accelerated approval
Combination drug guidance: Coordinate with FDA ONP about combination therapy regulations

[Treatments/Autophagy Enhancers](/therapeutics/autophagy-enhancers) — Related treatment strategy

Cross-Links

[Alzheimer's Disease](/diseases/alzheimers-disease) — Target disease for autophagy therapy
[Parkinson's Disease](/diseases/parkinsons-disease) — Alpha-synuclein clearance via autophagy
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — Protein aggregate clearance
[Huntington's Disease](/diseases/huntingtons) — Mutant [huntingtin](/proteins/huntingtin) clearance
[FTD](/diseases/frontotemporal-dementia) — TDP-43 aggregation clearance

[Autophagy Pathway](/mechanisms/autophagy-lysosome-pathway) — Core autophagy mechanism
[Proteostasis Network](/mechanisms/proteostasis-network) — Protein quality control systems
[TFEB Activation](/mechanisms/tfeb-activation) — Master regulator of lysosomal biogenesis
[mTOR Signaling](/mechanisms/mtor-signaling-neurodegeneration) — Autophagy inhibition pathway
[Lysosomal Function](/mechanisms/lysosomal-function)mechanisms/lysosomal-dysfunction) — Final destination for degradation

[mTOR Protein](/proteins/mtor-protein) — Central autophagy regulator
[TFEB Protein](/proteins/tfeb-protein) — Transcription factor for autophagy
[LC3 Protein](/proteins/lc3-protein) — Autophagosome marker
[p62 Protein](/proteins/p62-protein) — Selective autophagy receptor
[ULK1 Protein](/proteins/ulk1-protein) — Autophagy initiation complex

[Neurons](/cell-types/neurons) — Primary target cells for therapy
[Microglia](/cell-types/microglia) — Immune cells affected by autophagy modulation
[Astrocytes](/cell-types/astrocytes) — Support neuronal proteostasis

[Rapamycin](/therapeutics/rapamycin) — [mTOR](/mechanisms/mtor-signaling-pathway) inhibitor, autophagy inducer
[Trehalose](/therapeutics/trehalose) — Autophagy enhancer
[TFEB Activators](/therapeutics/tfeb-activators) — Direct TFEB targeting

References

[Unknown, TFEB and autophagy in neurodegeneration (Nat Rev Neurosci, 2020) (2020)](https://doi.org/10.1038/s41583-020-0301-5)

[Unknown, Autophagy-proteasome crosstalk (Mol Cell, 2019) (2019)](https://doi.org/10.1016/j.molcel.2019.09.005)

[Unknown, Alpha-synuclein and proteostasis (J Parkinsons Dis, 2018) (2018)](https://doi.org/10.3233/JPD-181337)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Transcriptional Autophagy-Lysosome Coupling](/hypothesis/h-ae1b2beb) — 0.72 · Target: FOXO1
[Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — 0.68 · Target: MCOLN1
[Autophagosome Maturation Checkpoint Control](/hypothesis/h-5e68b4ad) — 0.66 · Target: STX17
[Lysosomal Enzyme Trafficking Correction](/hypothesis/h-b3d6ecc2) — 0.65 · Target: IGF2R
[Lysosomal Membrane Repair Enhancement](/hypothesis/h-8986b8af) — 0.59 · Target: CHMP2B
[Mitochondrial-Lysosomal Contact Site Engineering](/hypothesis/h-0791836f) — 0.59 · Target: RAB7A
[Lysosomal Positioning Dynamics Modulation](/hypothesis/h-b295a9dd) — 0.56 · Target: LAMP1

Related Analyses:

[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Autophagy-Proteostasis Dual Activation discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

ideas-autophagy-proteostasis-dual-activation

▸Metadataorigin_type: v1_polymorphic_backfill

slug	ideas-autophagy-proteostasis-dual-activation
kg_node_id	None
entity_type	idea
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-74cf4753fcbb
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'ideas-autophagy-proteostasis-dual-activation'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

129

Outgoing

190

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Autophagy-Proteostasis Dual Activation

Overview

Pathway / Mechanism Diagram

Rubric Scores

Overview

Pathway / Mechanism Diagram

Rubric Scores

Action Plan

Action Plan

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

Cross-links

See Also

External Links

Implementation Roadmap

Estimated Timeline (4-5 years to IND)

Estimated Cost

Academic Centers (Key Opinion Leaders)

Potential Industry Partners

Risk Assessment

Regulatory Strategy

Cross-Links

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

Autophagy-Proteostasis Dual Activation

Overview

Pathway / Mechanism Diagram

Rubric Scores

Overview

Pathway / Mechanism Diagram

Rubric Scores

Action Plan

Action Plan

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

Cross-links

See Also

External Links

Implementation Roadmap

Estimated Timeline (4-5 years to IND)

Estimated Cost

Academic Centers (Key Opinion Leaders)

Potential Industry Partners

Risk Assessment

Regulatory Strategy

Related Treatment Approaches

Cross-Links

Related Diseases

Related Mechanisms

Related Proteins & Genes

Related Cell Types

Related Treatments

References

Related Hypotheses

Pathway Diagram

💬 Discussion